Generalizability of results from the National Lung Screening Trial
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Lung cancer is the major cause of cancer-related death worldwide, with a 5-year survival of only 16 %. Most lung cancer cases are diagnosed at an advanced incurable stage. As earlier stages have a better prognosis, the key to reducing mortality could be early diagnosis of the disease. At present, low-dose computed tomographic (CT) screening has shown promising data. Lung cancer death rates were reduced by 20 % when CT screening is compared to chest radiography in a high-risk group. There are many advantages of CT screening in lung cancer, however there are also some important issues that should be taken into account. Therefore, the applicability of the results to clinical practice is not clear yet. In this Commentary we discuss different aspects that play important roles in the balance between harms and benefits of screening, including overdiagnosis, availability of treatment options worldwide, ethical considerations, costs, and prolonged life expectancy. We conclude that clinicians should be cautious in generalizing findings to the total population of smokers and take into account that the use of lung cancer screening in clinical practice may have limitations.
- Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36. CrossRef
- National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. CrossRef
- Field JK, Smith RA, Aberle DR, Oudkerk M, Baldwin DR, Yankelevitz D, et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012;7:10–9. CrossRef
- Patel AR, Wedzicha JA, Hurst JR. Reduced lung-cancer mortality with CT screening. N Engl J Med. 2011;365:2035. (author reply 7-8). CrossRef
- Bach PB. Reduced lung-cancer mortality with CT screening. N Engl J Med. 2011;365(21):2036. (author reply 2037-8).
- Kaur-Knudsen D, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Nicotinic acetylcholine receptor polymorphism, smoking behavior, and tobacco-related cancer and lung and cardiovascular diseases: a cohort study. J Clin Oncol. 2011;29:2875–82. CrossRef
- Kohn MA. Reduced lung-cancer mortality with CT screening. N Engl J Med. 2011;365(21):2036–7. (author reply 2037-8).
- Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest. 2003;124:614–21. CrossRef
- Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003;289:313–22. CrossRef
- Heuvers ME, Stricker BH, Aerts JG. Generalizing lung-cancer screening results. N Engl J Med. 2012;366:192–3. CrossRef
- Underwood JM, Townsend JS, Tai E, Davis SP, Stewart SL, White A, et al. Racial and regional disparities in lung cancer incidence. Cancer. 2012;118(7):1910–8. doi:10.1002/cncr.26479.
- Mackenbach JP, Slobbe L, Looman CW, van der Heide A, Polder J, Garssen J. Sharp upturn of life expectancy in the Netherlands: effect of more health care for the elderly? Eur J Epidemiol. 2011;26(12):903–14.
- Mackenbach JP. The contribution of medical care to mortality decline: McKeown revisited. J Clin Epidemiol. 1996;49:1207–13. CrossRef
- Generalizability of results from the National Lung Screening Trial
European Journal of Epidemiology
Volume 27, Issue 9 , pp 669-672
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Lung cancer
- Lung cancer screening
- Generalization bias
- Industry Sectors
- Author Affiliations
- 1. Department of Respiratory Diseases and Tuberculosis, Erasmus Medical University Center, Rotterdam, The Netherlands
- 2. Department of Medicine, Mount Sinai Hospital, New York, NY, USA
- 3. Department of Epidemiology, Erasmus Medical University Center, Rotterdam, The Netherlands
- 4. Department of Internal Medicine, Erasmus Medical University Center, Rotterdam, The Netherlands
- 5. Department of Medical Informatics, Erasmus Medical University Center, Rotterdam, The Netherlands
- 6. Department of Respiratory Diseases and Tuberculosis, Amphia Hospital, Breda, The Netherlands